San Diego-based Prometheus Biosciences completed a $130 million equity financing led by Eventide Asset Management and RTW Investments for the development of inflammatory bowel disease treatment, according to a Nov. 9 press release.
The money will help speed up clinical development of PRA023, a potential antibody for IBD, the release said. The funds will also contribute to expanding Prometheus' 360 platform to help with drug discovery.
"We are pleased to have the support of such outstanding investors who share our dedication and vision to build the world's leading precision medicine company for IBD," Mark McKenna, president and CEO of Prometheus, said in a statement. "We are now well-positioned to advance the clinical development of our lead antibody program targeting TL1A-associated IBD and grow our emerging pipeline of precision medicine programs designed to deliver life-changing outcomes for patients."
Read the full press release here.